Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of HealthEquity, Inc. (NASDAQ:HQY). In a filing disclosed on July 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in HealthEquity stock on June 16th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $15,001 - $50,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/1/2025.
- Purchased $1,001 - $15,000 in shares of AppLovin NASDAQ: APP on 7/1/2025.
- Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 6/30/2025.
- Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 6/30/2025.
- Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 6/27/2025.
- Purchased $1,001 - $15,000 in shares of Xiaomi OTCMKTS: XIACF on 6/27/2025.
- Sold $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 6/27/2025.
- Sold $1,001 - $15,000 in shares of Willis Towers Watson Public NASDAQ: WTW on 6/26/2025.
- Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 6/26/2025.
- Sold $1,001 - $15,000 in shares of Liberty Media Corporation - Liberty Formula One Series C NASDAQ: FWONK on 6/26/2025.
HealthEquity Price Performance
Shares of HQY traded down $2.42 on Friday, hitting $97.70. The company's stock had a trading volume of 623,415 shares, compared to its average volume of 871,681. The company has a market capitalization of $8.45 billion, a PE ratio of 71.31, a PEG ratio of 1.51 and a beta of 0.49. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.06 and a quick ratio of 4.06. HealthEquity, Inc. has a fifty-two week low of $65.01 and a fifty-two week high of $116.65. The company has a 50 day moving average price of $101.65 and a 200 day moving average price of $98.48.
HealthEquity (NASDAQ:HQY - Get Free Report) last released its quarterly earnings data on Tuesday, June 3rd. The company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.16. The business had revenue of $330.80 million during the quarter, compared to analysts' expectations of $322.25 million. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. During the same quarter in the prior year, the company earned $0.80 EPS. On average, research analysts anticipate that HealthEquity, Inc. will post 2.32 earnings per share for the current fiscal year.
Insider Activity at HealthEquity
In other news, Director Jon Kessler sold 134,183 shares of the company's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $112.08, for a total transaction of $15,039,230.64. Following the transaction, the director owned 253,510 shares in the company, valued at approximately $28,413,400.80. This represents a 34.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Elimelech Rosner sold 58,000 shares of the company's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $112.56, for a total transaction of $6,528,480.00. Following the transaction, the executive vice president owned 75,689 shares in the company, valued at $8,519,553.84. This represents a 43.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 291,744 shares of company stock worth $32,705,007 over the last quarter. Company insiders own 1.50% of the company's stock.
Analyst Ratings Changes
Several brokerages recently issued reports on HQY. The Goldman Sachs Group raised their target price on shares of HealthEquity from $94.00 to $104.00 and gave the company a "neutral" rating in a research note on Wednesday, June 4th. Deutsche Bank Aktiengesellschaft raised their target price on shares of HealthEquity from $98.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, June 5th. JMP Securities raised their price objective on shares of HealthEquity from $110.00 to $117.00 and gave the stock a "market outperform" rating in a research report on Wednesday, June 4th. KeyCorp cut their price objective on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. Finally, Barrington Research raised their price objective on shares of HealthEquity from $112.00 to $125.00 and gave the stock an "outperform" rating in a research report on Thursday, June 5th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $118.55.
Read Our Latest Stock Report on HQY
Institutional Trading of HealthEquity
Several institutional investors have recently modified their holdings of HQY. Vanguard Group Inc. lifted its holdings in HealthEquity by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 8,976,091 shares of the company's stock valued at $861,256,000 after buying an additional 99,624 shares during the period. FMR LLC lifted its holdings in HealthEquity by 2.4% in the fourth quarter. FMR LLC now owns 5,415,800 shares of the company's stock valued at $519,646,000 after buying an additional 125,684 shares during the period. Invesco Ltd. lifted its holdings in HealthEquity by 50.6% in the first quarter. Invesco Ltd. now owns 2,446,198 shares of the company's stock valued at $216,171,000 after buying an additional 821,425 shares during the period. Geode Capital Management LLC lifted its holdings in HealthEquity by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 2,089,398 shares of the company's stock valued at $200,522,000 after buying an additional 10,421 shares during the period. Finally, Brown Advisory Inc. lifted its holdings in HealthEquity by 12.0% in the fourth quarter. Brown Advisory Inc. now owns 2,086,026 shares of the company's stock valued at $200,154,000 after buying an additional 224,016 shares during the period. Institutional investors own 99.55% of the company's stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
HealthEquity Company Profile
(
Get Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Articles
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
